Jared Watkin

Executive Vice President of Diabetes Care, Abbott Laboratories

Search every verified Jared Watkin interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. In a 2014 presentation at the European Association for the Study of Diabetes meeting in Vienna, Jared Watkin, then Divisional Vice President of Technical Operations for Abbott Diabetes Care, discussed the company's FreeStyle Libre flash glucose monitoring system. Watkin stated that the product was designed as an alternative to blood glucose monitoring, describing it as a 14-day, factory-calibrated sensor that does not require finger-stick calibrations. He noted that the system achieved a MARD of 11.4% and that 99.7% of results fell within zones A and B of the consensus error grid. Watkin attributed the system's factory calibration capability to Abbott's "wired enzyme" chemistry, which he said allows for stable sensor performance. He acknowledged that worldwide CGM penetration was less than 5%, citing cost, lack of reimbursement, and data interpretation challenges as factors. Watkin added that Abbott was conducting randomized controlled trials to generate outcome data to support reimbursement positions.